Beacon's rare eye disease gene therapy signals vision function improvements in early phase 2 data
The company's gene therapy made for improvements in visual function for patients with X-linked retinitis pigmentosa at a six month interim of its phase 2 study.
The company's gene therapy made for improvements in visual function for patients with X-linked retinitis pigmentosa at a six month interim of its phase 2 study.
